Introduction to the main functions and effects of lenvatinib/lenvatinib (Lenvima)

Lenvatinib is an oral small molecule multi-receptor tyrosine kinase inhibitor. Its mechanism of action focuses on inhibiting angiogenesis and signaling pathways in the tumor microenvironment. Specific targets include VEGFR1–3, FGFR1–4, PDGFRα, RET and KIT, etc., which enable it to resist angiogenesis and intervene in signals related to the growth and migration of tumor cells. Based on the pharmacological characteristics of this multi-pathway inhibition, lenvatinib has shown therapeutic value in a variety of solid tumors and has been gradually incorporated into the treatment system of different cancer types.

The main indications currently approved by international and domestic regulatory approvals or recommended by guidelines include: radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or metastatic liver cancer (uHCC; used as a first-line option in some countries) and in combination with other drugs for advanced renal cell carcinoma (RCC); in addition, lenvatinib also shows considerable synergistic potential in combination with immune checkpoint inhibitors for some tumors such as endometrial cancer. Its anti-tumor effect is often explained as "suppressing tumor blood supply and reshaping the immune microenvironment", which makes lenvatinib clinically valuable in both single-agent anti-angiogenic therapy and combination strategies with immunotherapy. When using the drug, attention should be paid to its toxicity spectrum: common ones include hypertension, proteinuria, thyroid dysfunction, fatigue or gastrointestinal reactions, etc. Clinical management emphasizes early monitoring and dose adjustment to maintain efficacy while controlling adverse reactions.

Overall, lenvatinib represents an important part of the multi-target small molecule inhibitors in the treatment of solid tumors. Its application in multiple indications such as liver cancer, kidney cancer, thyroid cancer and endometrial cancer is being continuously refined with the deepening of combination strategies and molecular classification, thereby providing individualized treatment options for more patients with clear molecular characteristics.

Reference materials:https://www.lenvima.com/